Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ChemoCentryx stock | $34.57

Learn how to easily invest in ChemoCentryx stock.

ChemoCentryx Inc is a biotechnology business based in the US. ChemoCentryx shares (CCXI) are listed on the NASDAQ and all prices are listed in US Dollars. ChemoCentryx employs 133 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ChemoCentryx

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CCXI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ChemoCentryx stock price (NASDAQ: CCXI)

Use our graph to track the performance of CCXI stocks over time.

ChemoCentryx shares at a glance

Information last updated 2021-10-16.
Latest market close$34.57
52-week range$9.53 - $70.29
50-day moving average $20.53
200-day moving average $21.22
Wall St. target price$70.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.77

Buy ChemoCentryx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ChemoCentryx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ChemoCentryx price performance over time

Historical closes compared with the close of $34.57 from 2021-10-22

1 week (2021-10-15) 0.29%
1 month (2021-09-24) 89.95%
3 months (2021-07-23) 140.57%
6 months (2021-04-23) -24.68%
1 year (2020-10-23) -41.21%
2 years (2019-10-23) 349.54%
3 years (2018-10-23) 211.16%
5 years (2016-10-21) 453.12%

ChemoCentryx financials

Revenue TTM $21.6 million
Gross profit TTM $-12,991,000
Return on assets TTM -15.04%
Return on equity TTM -32.7%
Profit margin 0%
Book value $4.73
Market capitalisation $2.4 billion

TTM: trailing 12 months

Shorting ChemoCentryx shares

There are currently 3.9 million ChemoCentryx shares held short by investors – that's known as ChemoCentryx's "short interest". This figure is 4.5% up from 3.7 million last month.

There are a few different ways that this level of interest in shorting ChemoCentryx shares can be evaluated.

ChemoCentryx's "short interest ratio" (SIR)

ChemoCentryx's "short interest ratio" (SIR) is the quantity of ChemoCentryx shares currently shorted divided by the average quantity of ChemoCentryx shares traded daily (recently around 1.6 million). ChemoCentryx's SIR currently stands at 2.38. In other words for every 100,000 ChemoCentryx shares traded daily on the market, roughly 2380 shares are currently held short.

However ChemoCentryx's short interest can also be evaluated against the total number of ChemoCentryx shares, or, against the total number of tradable ChemoCentryx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ChemoCentryx's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 ChemoCentryx shares in existence, roughly 60 shares are currently held short) or 0.0777% of the tradable shares (for every 100,000 tradable ChemoCentryx shares, roughly 78 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ChemoCentryx.

Find out more about how you can short ChemoCentryx stock.

ChemoCentryx share dividends

We're not expecting ChemoCentryx to pay a dividend over the next 12 months.

ChemoCentryx share price volatility

Over the last 12 months, ChemoCentryx's shares have ranged in value from as little as $9.53 up to $70.29. A popular way to gauge a stock's volatility is its "beta".

CCXI.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChemoCentryx's is 1.4148. This would suggest that ChemoCentryx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ChemoCentryx overview

ChemoCentryx, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Frequently asked questions

What percentage of ChemoCentryx is owned by insiders or institutions?
Currently 17.592% of ChemoCentryx shares are held by insiders and 64.797% by institutions.
How many people work for ChemoCentryx?
Latest data suggests 133 work at ChemoCentryx.
When does the fiscal year end for ChemoCentryx?
ChemoCentryx's fiscal year ends in December.
Where is ChemoCentryx based?
ChemoCentryx's address is: 835 Industrial Avenue, San Carlos, CA, United States, 94070
What is ChemoCentryx's ISIN number?
ChemoCentryx's international securities identification number is: US16383L1061
What is ChemoCentryx's CUSIP number?
ChemoCentryx's Committee on Uniform Securities Identification Procedures number is: 16383L106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site